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The Royal Free Sheila Sherlock Liver Centre and University Department of Surgery, Royal Free Hospital and UCL, London, UKSummary to HCV in the non-transplant liver but there are signiﬁcantlyHCV related liver disease is the most common indication for liver
transplantation. Recurrence of HCV infection is universal and has
a substantial impact on patient and graft survival. Immunosup-
pression is a major factor responsible for the accelerated recur-
rence and compressed natural history of recurrent HCV
infection. Accumulating experience has provided data to support
certain strategies for immunosuppressive regimens.
From the available evidence, more severe recurrence results from
repeated bolus corticosteroid therapy and anti-lymphocyte anti-
bodies used to treat rejection. Low dose and slow tapering of ste-
roids are better than high dose maintenance and/or rapid
tapering. Recent meta-analyses favour steroid-free regimens
but these are complicated to interpret as the absence of steroids
may simply represent less immunopotency.
There is no difference in HCV recurrence between tacrolimus and
cyclosporine regimens, but tacrolimus increases graft and patient
survival in HCV transplanted patients. There may be a beneﬁcial
effect of maintenance azathioprine given for 6 months or longer.
There is no conclusive evidence for beneﬁt of mycophenolate and
interleukin-2 receptor blockers. Few data are available for mTOR
inhibitors. Better evidence is needed to establish the optimal
immunosuppressive regimen for HCV recipients and more ran-
domized trials should be performed.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.IntroductionHepatitis C virus (HCV) related cirrhosis is currently the most fre-
quent indication for liver transplantation (LT). However, graft
reinfection with HCV is universal in all patients who are HCV-
RNA PCR positive at transplantation, and the progression of ﬁbro-
sis is accelerated compared to non-transplanted patients [1],
resulting in cirrhosis in about 30% of recipients by 5 years [2],
with rapid decompensation and reduced survival thereafter
[3,4]. Chronic HCV infection in the liver allograft looks similarJournal of Hepatology 20
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A variety of pre-transplant, operative, and post-transplant fac-
tors have been associated with severity of HCV recurrence.
Immunosuppression is a major factor and is still an area of uncer-
tainty, due to the lack of good evidence for what may be better or
worse [6]. Immunosuppression for HCV patients represents a ﬁne
balance between suppressing immunity and maintaining optimal
host viral responses. A major problem is that a universal measure
reﬂecting immunopotency of different immunosuppressive regi-
mens does not exist. In addition, there are few randomized trials.
Thus, evaluating the relationship between severity of HCV recur-
rence and immunosuppression remains a descriptive process,
assessing type, dose, and duration of immunosuppressive drugs.
Moreover, other important factors such as age and quality of
the donor organ need to be taken into account [7], and often these
are not evaluated when assessing different immunosuppressive
regimens [8]. There is little uniformity in immunosuppression reg-
imens and wide variations in the timing and description of the
evaluation of HCV recurrence: bothmake it difﬁcult to draw useful
conclusions for clinical practice. A recent international survey
reviewed immunosuppression policy for HCV-transplanted
patients in 81 centres [9]: a third had speciﬁc differences in immu-
nosuppression between HCV vs. non-HCV recipients and most of
the rest used variations of tacrolimus-based therapies.Calcineurin inhibitors (CNIs)
Mechanisms of action and experimental data
The CNIs cyclosporine A (CyA) and tacrolimus (Tac) are the prin-
cipal maintenance immunosuppressives. They inhibit calcineurin,
a key enzyme for IL-2 production by T-cells, which recruits and
activates CD4 T-cells, and via cytokine induction, affects cytotoxic
CD8 cells, NK cells, and B cell activation [10]. Thus, the amount of
IL-2 determines the magnitude of the immune response and
rejection. HCV infection may inﬂuence CNI metabolism. A retro-
spective evaluation [11] of HCV and alcoholic liver disease
(ALD) patients showed that, for both CNI, signiﬁcantly lower
doses were needed to achieve similar blood concentrations in
HCV compared to ALD patients.
In vitro, CyA inhibits HCV replication by speciﬁc blockade of
cyclophyllins (intracellular ligands of CyA) that bind to HCV non-
structural protein 5B, but in concentrations greater than therapeu-
tic levels in man (1–10 lg/ml). There is controversy about effects
in vivo. Tac does not have any anti-HCV activity [12,13].12 vol. 56 j 973–983
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Clinical studies – observational
In a consecutive series of 193 HCV transplant recipients at the
Royal Free Hospital [14] with 96 receiving Tac and 92 CyA, there
were no differences in ﬁbrosis progression nor survival. From the
same population of HCV transplant recipients, 96 patients with at
least 3 years follow-up were evaluated to assess changes in ﬁbro-
sis and identify factors potentially associated with slower ﬁbrosis
progression after LT (Ishak score and Sirius red for digital image
analysis of collagen, expressed as Collagen Proportionate Area –
CPA) [15]: sustained virological response (SVR) (p = 0.01) and
Tac plus AZA (p = 0.024) were associated with slower ﬁbrosis pro-
gression, based on CPA.
In a retrospective study of 516 HCV patients published in
abstract form, Tac improved the 5-year survival compared to
CyA (75% vs. 67%, p = 0.02) despite there being neither signiﬁcant
difference in 1-year survival nor in ﬁbrosis progression [16].
In a UNOS based analysis [17], HCV recipients receiving CyA at
discharge from hospital had three-year patient and graft survival
of 76.8% and 71.5%, respectively vs. 79.9% and 75% in the Tac group.
CyA treated patients were at increased risk of death (HR 1.17;
95% CI 1.01–1.36), graft failure (HR 1.19; 95% CI 1.04–1.35) and
biopsy-conﬁrmed acute rejection (HR 2.03; 95% CI 1.54–2.67).
CyAmay inﬂuence the efﬁcacyof antiviral therapy in transplant
recipients; CyA was a predictor of sustained virological response
(SVR) in one cohort of 99 patients, but 57% also had azathioprine
(AZA) which was not evaluated [18]. In 115 patients, treatment
with CyA and low dose IFNa resulted in greater inhibition of HCV
replication compared to either CyA or IFNa alone [19]. In a retro-
spective study of 446 recipients published by Selzner 2009 et al.
[20], 39% (172 patients) received treatment; SVR was higher in
patients treated with CyA (56%) thanwith Tac (44%) but this failed
to reach statistical signiﬁcance. Recently, another retrospective
analysis of 464 recipients treated for HCV recurrence in 12 Italian
centres evaluated the impact of CNIs on SVR [21]. End of treatment
response was signiﬁcantly higher in those treated with CyA (64%)
thanwith Tac (54.5%) (p = 0.04), but therewas no difference either
in SVR or in survival. From the same database, Rendina et al. [22]
reported an SVR rate of 35%, which signiﬁcantly improved on
patient survival. The rate of acute/chronic rejection in this popula-
tion under interferon was around 6%.
In 16 living donor recipients [23] with Tac/corticosteroids (Cs)
induction and conversion to CyA, a subsequent pre-emptive anti-
viral therapy was used in 11 patients: only three showed SVR
(21.4%). In 120 non-transplanted patients with chronic HCV trea-
ted with IFN-a2b in combination with CyA, SVR was increased
[24]. In another study, in 10 patients there was an ALT reduction
but no virological response [22].
Clinical studies – randomized trials and meta-analyses (Table 1)
An early randomized controlled trial (RCT) [25] randomized 50
HCV recipients to Tac (n = 25) or CyA; no difference in HCV recur-
rence nor in graft and patient survival was observed. Martin et al.
[26] randomized 79 patients to Tac (n = 38) or CyA (n = 41);
despite signiﬁcantly higher HCV RNA levels at 1, 6, and
12 months in CyA-treated recipients, there was no difference in
histological HCV recurrence or in patient survival.
A multicentre prospective (RCT) assessed Tac/corticosteroids
(Cs) vs. Tac/AZA/Cs [27] in a subgroup of HCV recipients: 50 dual974 Journal of Hepatology 201and 35 in triple therapy, with tapering of steroids at 3 months,
and then steroid withdrawal in both arms. Despite increased
biopsy proven acute rejection in the dual regimen (p = 0.008),
there was no difference in patient and graft survival.
In another RCT, a subgroup of 20 HCV patients was randomized
to Tac, and 15 to Tac/Cs [28]. A steroid taperwas instituted starting
at a very high dose of 100 mg bd of methylprednisolone on day 1
post LT, decreasing to 20 mg/day by day 6, andweaned completely
between 9 and 12 months. The incidence and severity of graft hep-
atitis C at 3 years was reduced in Tac alone (47%) compared with
Tac + Cs (67%) (p = n.s.), but at 5 years there were no statistically
signiﬁcant differences in ﬁbrosis score nor in survival rates.
The Valencia group [29] reported an RCT comparing Tac vs.
CyA both combined with steroids in 90 HCV-positive recipients:
severe or cholestatic hepatitis in CyA (12/44) and in Tac (15/46)
groups was similar.
More recently Manousou et al. [30] randomized patients to Tac
monotherapy (n = 54) vs. triple therapy (n = 49) (Tac 0.1 mg/kg/
day, low dose prednisone 20 mg/day and AZA 1 mg/kg). Steroids
were tapered to zero by 3–6 months, and follow-up was a mean
of 53.5 months. The predetermined end-point of stage 4 Ishak
ﬁbrosis was reached in 17 monotherapy and 10 triple therapy
(p = 0.04), with slower ﬁbrosis progression in triple therapy
patients (p = 0.048). Allocated therapy and histological acute hep-
atitis were independently associated with stage 4 ﬁbrosis. HVPG
increased to 10 mmHg or higher, more rapidly in monotherapy
vs. triple therapy patients (p = 0.038). In this study, long-termmain-
tenance immunosuppression with AZA and shorter term predniso-
lone together with Tac resulted in a slower onset of histologically
proven severe ﬁbrosis and portal hypertension in comparison to
Tac alone. This was independent of other known factors affecting
ﬁbrosis (e.g. donor age) and the fact that more rejection using proto-
col biopsies was seen in the triple therapy group [31]. There were no
survival differences between the two treatment arms. This trial, for
which the premise was that no steroid maintenance and less immu-
nosuppression i.e. Tac monotherapy would result in less severe HCV
recurrence, showed that AZA and low dose steroids have a beneﬁcial
modulating inﬂuence on HCV recurrence.
In 38 HCV recipients randomized to continue Tac, or switch to
CyA, the latter led to a modest reduction of HCV RNA titre and
appeared to enhance the response to PEG IFN/ribavirin [32]. A ran-
domized trial [33] of 81 recurrentHCV recipients evaluateddisease
progression using paired liver biopsies and HVPG measurements.
SVR occurred in a higher proportion of patients treated with CyA
compared to Tac but the difference was not signiﬁcant.
In a recent prospective study of 253 HCV recipients in Valen-
cia, Berenguer et al. compared Tac vs. CyA-based immunosup-
pression in HCV recipients. There was no difference between
the two CNIs with regard to the severity of recurrent HCV, the
occurrence of severe cholestatic hepatitis and neither in patient
nor graft survival at 1 and 7 years [34].
A meta-analysis of 16 RCT compared Tac (1899 patients) vs.
CyA (1914 patients) in LT [35,36]. Data on HCV cohorts showed
that Tac was superior to cyclosporine in improving graft (RR
0.78, 95% CI 0.68–0.89) and patient survival (RR 0.85, 95% CI
0.73–0.99) and preventing acute rejection (RR 0.82, 95% CI
0.77–0.88) and steroid resistant rejection (RR 0.57, 95% CI 0.46–
0.71), but Tac increased the risk of diabetes.
Another meta-analysis [7] of ﬁve randomized studies showed
no difference in patient and graft survival with respect to2 vol. 56 j 973–983
Table 1. Major recent studies with calcineurin inhibitors.
Authors, year No. of patients Variables Outcome Results p value
Martin et al., 
2004
Tac-based n = 38
CyA-based n = 41 
Tac/AZA/Cs vs.
CyA/AZA/Cs
Histological HCV recurrence
Change in viral load
Graft/Patient survival
• Cumulative probability 
of HCV recurrence in 
Tac 0.32 vs. 0.31 in CyA 
group
• 
higher in CyA vs. Tac 
group
• Similar graft/patient 
survival
n.s.
0.032
n.s.
Gonzalez et al., 
2005
Dual 50 (55%)
Triple 35 (40%)
Tac/Cs (D) vs.
Tac/Cs/AZA (T)
BPAR
12 and 24 mo 
Patient/graft survival
BPAR: D 24 vs. T 7
12 mo patient and graft 
survival  
24 mo patient and graft 
survival 
0.008
n.s.
n.s.
Margarit et al., 
2005 
Tac 28 
(HCV 20-71%)
Tac/Cs 32 
(HCV 15-47%)
Tac vs.
Tac/Cs
Graft status at 3 yr
Survival
• Severity graft hepatitis 
Tac 47% vs. Tac/Cs 
67%  
• 5 year survival both 61% 
n.s.
n.s.
Berenguer et 
al., 2006
90 HCV CyA vs. Tac Time to acute hepatitis 
Severe hepatitis 
Death
CyA 92 days vs. Tac 59 
days
12 (27%) vs. 15 (32%)
6 (13%)-6 (13%)
0.02
n.s.
Manousou et 
al., 2009
103 HCV Tac 54 (MT)
Tac/AZA/Cs 49 (TT)
HVPG ≥10 mmHg 
MT 17 vs. TT 10
MT 10 vs. TT 2
0.04
0.048
0.038
Berenguer et 
al., 2010*
253 HCV CyA-based 136 
Tac-based 117
Severe disease
Patient survival 1 yr
Patient survival 7 yr
SVR after antiviral therapy
CyA 27% vs. Tac 26%
CyA 83% vs. Tac 78%
CyA 67% vs. Tac 64%
CyA 38% vs. Tac 39%
0.68
0.4
0.9
Irish et al., 
2010
8809 HCV patients
UNOS database –
Retrospective 
analysis
CyA vs. Tac
(maintenance 
immunosuppression 
prior to discharge)
1 yr patient and graft survival
3 yr patient and graft survival
BPAR 
• CyA patient 84.6 ± 1.3% 
– graft 88 ± 1.2% 
Tac patient 86.5 ± 0.4% 
– graft 89.9 ± 0.3%
• CyA patient 71.5 ± 1.7% 
– graft 76.8 ± 1.7% 
Tac patient 75.5 ± 0.5% 
– graft 79.9 ± 0.5%
• CyA-treated 19.9% vs. 
Tac-treated 9%
#CyA vs. Tac
HR for death 
1.3 (95% CI: 
1.07-1.58)
HR for graft 
failure 1.26 
(95% CI: 
1.06-1.5)
HR for BPAR 
2.03 (95% CI: 
1.54-2.67)
HCV RNA significantly
TT slower fibrosis
Ishak stage 4 fibrosis
BPAR, biopsy proven acute rejection; n.s., not signiﬁcant; HR, hazard ratio.
⁄Series of patients prospectively allocated to either Tac or CyA; ‘‘quasi-randomized’’ study with CyA or Tac in combination with prednisone or mycophenolate mofetil.
#Propensity score-adjusted result.
JOURNAL OF HEPATOLOGYmaintenance CNI. Data on histological HCV progression based on
protocol biopsies was available in only 1 study. In studies favour-
ing CyA [37–39], use of azathioprine was more frequent with
CyA, than with Tac, but was not evaluated speciﬁcally.
In conclusion, CyA has anti-HCV effects in vitro but the clinical
beneﬁt has not been established. Tac is the preferred CNI in liver
transplant recipients as it increases graft and patient survival
compared to CyA, in both non-HCV and HCV cohorts. Further
studies are needed on CNI and antiviral therapy combined.Corticosteroids
Viral and molecular background
Steroids are used as parenteral boluses for acute cellular rejection, as
part of induction protocols, and asmaintenance immunosuppression
together with other drugs. HCV viral load increases after steroid
boluses, and multiple boluses are associated with worse recurrentJournal of Hepatology 201disease. However, the effects of steroidmaintenance are still contro-
versial [40]. In an in vitro replicon model using Huh-7 ET cells, clini-
cally relevant concentrations of dexamethasone and prednisolone
did not enhance, but slightly reduced HCV replication [41]. In vivo,
steroids may inﬂuence severity of HCV recurrence by modulating
lymphocyte response and immune surveillance.
Steroid boluses
Steroid boluses are associated with increased viral replication: 4–
10-fold in vivo following 3 daily i.v. injections of 1 g of methyl-
prednisolone [42]. In 241 recipients with HCV, transplanted
between 1988 and 1996 in two different centres [43], the ﬁbrosis
progression rate increased when i.v. methylprednisolone boluses
were more than 3. The same group reported that recurrent cir-
rhosis was associated with 3 ± 2.2 boluses vs. 1.5 ± 2.1 in those
without cirrhosis [44].
In 234 HCV transplanted patients [45], repeated treatment for
rejection with Cs signiﬁcantly increased the risk of accelerated2 vol. 56 j 973–983 975
Frontiers in Liver Transplantation
progression of graft hepatitis and graft failure, but a single pulse
of methylprednisolone was not statistically associated with
increased ﬁbrosis. In another study [46], a comparison of number
of boluses during 1999–2000 (mean 11) vs. 2001–2004 (mean 4)
showed no difference between severe and mild HCV recurrence
with respect to boluses, but maintenance steroids were used dif-
ferently in these periods.
Maintenance steroids
Clinical studies – observational
A survey [9] of 36 centres in the US and 45 non US, documented
that 6 (7.4%) used steroid-free protocols, 9 (11%) discontinued ste-
roids within a week, 56% within 3 months and 98%within the ﬁrst
year. The duration of steroid therapy was signiﬁcantly shorter in
US, than non-US programs. (10.8 vs. 29.4 weeks, p <0.001).
In the comparative study [46] mentioned above, the 1999–
2000 cohort, in which neither slow tapering of steroids nor dual
maintenance with steroids were used, showed a signiﬁcantly
higher rate of severe disease (48%) compared to the 2001–2004
(29%) cohort, despite presumably the use of younger donors in
the earlier transplant era. In the most recent cohort, use of triple
or quadruple regimens was far less (10% vs. 25%; p = 0.001), with
fewer boluses of methylprednisolone (4 vs. 11; p = 0.002), and the
duration of maintenance prednisone was longer (350 days vs.
249 days; p <0.0001) [46]. This suggests that initial less potent
immunosuppression and/or longer maintenance use of steroids
is associated with less severe disease.
These data concur with our data [14], which documented that
short term maintenance steroids (up to 6 months) was associated
with less ﬁbrosis progression (O R 0.4, 95% CI 0.23–0.83). Another
study evaluated 39 patients: rapid tapering of steroids (group A),
was compared to slow tapering and withdrawal, 25 months after
LT (group B) [47]. At 12 months after LT, advanced ﬁbrosis was
greater in group A compared to group B (42.1% vs. 7.6%). More-
over, one and two-year advanced ﬁbrosis-free survivals were
65.2% vs. 93.7% (p = 0.03) and 60.8% vs. 93.7% (p = 0.02) in group
A compared to group B, respectively (Table 2).
In 80 patients, at both 6 and 12 months after transplantation
[48], higher median daily prednisone doses resulted in less mod-
erate/severe recurrent HCV compared to lower doses: at
12 months 35.7% vs. 66% (p = 0.02).
Clinical studies – randomized trials and meta-analyses
In our recent randomised trial of 103 LT patients, [30], despite
more histologically proven and treated rejection episodes (identi-
ﬁed by protocol biopsies) [31], treatment with Tac and mainte-
nance steroids and long term AZA resulted in slower onset of
histologically proven severe ﬁbrosis and portal hypertension,
without statistical differences in the rates of renal dysfunction,
retransplantation and death. The ﬁbrosis progression rate in this
group is the lowest reported to date (Ishak stage 4 at 3 years
23%). This suggests the ‘‘beneﬁcial’’ effect of maintenance steroids
is more important than the detrimental effect of bolus steroids.
Another RCT compared steroid maintenance (Cya–AZA–basil-
iximab–steroids) (n = 74) vs. steroid-free (Cya, AZA, basiliximab)
(n = 66) regimens in HCV liver transplanted patients [49]. At
12 months, there was no signiﬁcant difference in histological
recurrence (41% steroid vs. 37.5% in non-steroid, p = 0.35). The
steroid-free regimen was associated with lower treatment failure
rate (death, graft loss, withdrawal for adverse effects).976 Journal of Hepatology 201Steroid avoidance
Clinical studies – observational
Among 28 HCV patients after living donor transplantation, 18
received CNI, MMF, and anti-CD25 antibody, and 10 received ste-
roid based immunosuppression (CNI and steroids ± MMF ±
antiCD25 antibody) [50]. The steroid-free group had less CMV
infection (p = 0.049), and less HCV recurrence at 1 year, 18% vs.
46% (p = 0.009).
Clinical studies – randomized trials and meta-analyses
Steroid avoidance was evaluated in a multicenter RCT [51] with
312 patients: (1) Tac and steroids; (2) Tac, steroids, and MMF;
and (3) daclizumab induction, Tac, and MMF. Patient and graft
survival did not differ signiﬁcantly between treatment arms.
Freedom from HCV recurrence at one year was 62%, 60%, and
67% in the three groups respectively; freedom from rejection
was signiﬁcantly higher in the corticosteroid-free immunosup-
pression group. Long-term follow-up is not yet available.
Llado et al. randomized 198 LT patients to receive basiliximab
and CyA either with prednisone 0.5 mg/kg/day, tapering to
0.15 mg/kg/day at day 90, or without prednisone [52]. Amongst
these, therewere 89HCV-infected patients,with a cumulative per-
centage of protocol biopsies with grade 3 or 4 ﬁbrosis (Scheuer
classiﬁcation) at 6 months, 1 year, and 2 years of 0%, 8%, and 22%
in the non-Cs group, compared to 8%, 19%, and 31% in the Cs group,
respectively (p = n.s.) (Table 3). The authors concluded that immu-
nosuppression without steroids in HCV patients was safe, and
improvedhistological short termevolutionofHCV recurrencewith
a reduction in bacterial infections and metabolic complications.
Kato et al. randomized 70 HCV patients to receive Tac and dac-
lizumab vs. Tac and steroids during 1999–2001, and Tac with
MMF and daclizumab vs. Tac with MMF and steroids during
2002–2005 [53]. No signiﬁcant differences were found in mean
ﬁbrosis stage, between the various treatment groups, either aver-
aging across the two time periods or during these periods them-
selves. Patients on steroid-free regimens had signiﬁcantly less
diabetes mellitus and wound infections.
In a recent RCT in 110 patients, early Cs-free immunosuppres-
sion was the goal [54]. All patients received Tac/Cs and at 2 weeks
post-transplant were randomized to placebo (14 HCV) or steroids
(16 HCV). Recurrent cirrhosis was not inﬂuenced by continuous
steroid therapy but was more frequent in those receiving steroid
boluses.
A meta-analysis [55] evaluated 30 publications, comprising 19
RCT comparing steroid-free with steroid-based immunosuppres-
sion, including both HCV and non-HCV recipients. There were no
differences in death, graft loss and infection rates. HCV recur-
rence was lower with steroid avoidance, and although no individ-
ual trial reached statistical signiﬁcance, meta-analysis showed an
advantage of approximately 10% (RR 0.90; 95% CI: 0.82–0.99,
p = 0.03). However, there was considerable clinical heterogeneity,
and it was difﬁcult to assess the global immunopotency of each
regimen. No evaluation of concomitant immunosuppression
was made. Data on ﬁbrosis progression and on steroid dose and
withdrawal were not reported.
A more recent meta-analysis [56] evaluated steroid with-
drawal in LT for any indication in 2590 patients from 21 RCT.
There were no differences between Cs-free and Cs-based proto-
cols in nearly all analyzed outcomes. In 14 studies (1418
patients) evaluating an HCV transplanted population, there was2 vol. 56 j 973–983
Table 2. Maintenance corticosteroids for HCV-positive recipients: the case for.
Author, year Immunosuppression No. patients
(total)
Steroids
Brillanti et al., 
2002
CyA/Tac, Pred, AZA
CyA/Tac, Pred
80 n = 36 <7.5 mg at 6 mo
n = 44 Slow tapering to 24 mo - Prednisolone at 6 mo associated with disease- 
free graft survival
Samonakis et al., 
2005 
CyA or Tac-based 
combination 
47 monotherapy
193 Median maintenance steroids 
4 mo
Berenguer et al., 
2006 
CyA or Tac-based 
combination
HG, 52
RC, 90
Pred >6 mo: 65% HG, 81% RC
Pred >1 yr: 21% HG, 46% RC
Severe disease less in RC due to avoid 
rapid tapering and potent induction 
immunosuppression
Vivarelli et al., 
2007
Tac-based 23
16
Group A: rapid tapering/
withdrawal 3 mo
Group B: slow tapering/
withdrawal 25 mo
Slow tapering of steroids associated with 
reduced progression of recurrent HCV
Kato et al.,
2007 
Tac+Dacl vs. Tac+Cs
Tac+Dacl+MMF vs. 
Tac+Cs+MMF
31
39
Complete taper off within 3 mo 
in the control groups - Acute rejection episode the 1st  year correlated 
- No difference in graft survival 
Manousou et al., 
2009 
Tac vs.
Tac/AZA/Pred
54
49
Pred tapered/stopped between 
3-6 mo
Short term steroids associated with slower 
and portal hypertension
or indefinitely
- Slow tapering maintenance steroids beneficial
Short term steroids, less fibrosis progression
- No difference in fibrosis scores
with higher fibrosis
onset of histologically proven severe fibrosis
Interpretation (fibrosis, survival)
Tac, tacrolimus; AZA, azathioprine; Pred, prednisolone; CyA, cyclosporin A; Dacl, daclizumab; MMF, mycophenolate mofetil; HG, historical group; RC, recent cohort.
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rence (RR 1.15), acute graft hepatitis (OR 3.15), and treatment
failure (death, graft loss, withdrawal) (OR 1.87). Cumulative
meta-analysis showed a relatively consistent reduction in the
HCV recurrence rate between 2005 and 2008. However, dose
and rapidity of steroid withdrawal were not evaluated and again
results are difﬁcult to interpret due to heterogeneity in the stud-
ies (Table 3).
In conclusion, randomized trials in which the only variable is
maintenance steroids are needed. The ‘‘protective role’’ of slow
steroid withdrawal shown in several studies also requires further
investigation, as steroids may reduce the immune mediated dam-
age of infected liver cells. Although HCV viraemia levels normally
increase during steroid treatment, a rapid decrease in steroid
immunosuppression could expose HCV-infected cells to a par-
tially restored immune system and attack. This could determine
a worse graft evolution in patients undergoing the faster CS
tapering protocols [46] [14].Azathioprine (AZA) and mycophenolate mofetil (MMF)
Mechanisms of action and experimental data
AZA and MMF are antimetabolites. AZA is a prodrug of 6-mercap-
topurine, which by inhibiting inosine monophosphate dehydro-
genase (IMPDH) reduces purine synthesis, affecting DNA, RNA,
other nucleotides, and proteins [57]. T and B lymphocytes are
dependent on de novo synthesis of purines for their proliferation.
Mycophenolic acid (MPA)-the active metabolite of MMF, is a
selective non-competitive inhibitor of IMPDH. AZA is more mye-
lotoxic and hepatotoxic than MMF, but MMF causes diarrhea in
30% of patients, and tissue invasive CMV infection, especially at
3 g/day. These side effects are reduced with 2 g/day. Both drugs
have in vitro antiviral activity against HCV. In one in vivo cross-
over study, MMF as a substitute for AZA increased viral loadJournal of Hepatology 201but there was no ALT change [58]. Whether either drug has an
effect on the severity of HCV recurrence is still debated.
Clinical studies – azathioprine
Ten studies have data on AZA and severity of HCV recurrence [57]
[59]: in six it was decreased, in four there was similar severity
and no study was associated with increased severity (Table 4).
This effect was statistically signiﬁcant in a cohort of 66 patients
[60]: less recurrence (p <0.005), less progression (p = 0.014). In
another study of 92 patients [61], AZA was associated with less
cirrhosis, death or retransplantation (RR 0.37 [95% CI 0.14–
0.92], p = 0.033). A short (<6 months) duration of maintenance
with AZA was a risk factor for severe recurrent disease [8]. Our
data showed that long term AZA was associated with a lower risk
of allograft failure and mortality [14].
Moreover, in our RCT [30], long term maintenance immuno-
suppression with AZA (and short term low dose prednisone) with
Tac resulted in slower progression to severe ﬁbrosis and portal
hypertension in comparison to Tac monotherapy. Another multi-
centre trial had 65 HCV transplant recipients randomized to Tac/
steroids vs. Tac/steroids/AZA [27]. AZA was associated with less
acute rejection but no differences in graft and patient survival.
In another randomized study [62], a direct comparison
between MMF and AZA in 54 HCV-positive transplant recipients
was not evaluated, but there were no differences in patient and
graft survival at 1 year.
Clinical studies – MMF
Seventeen studies have data on MMF and severity of HCV recur-
rence: only two found decreased severity, (in one there was no
multivariate analysis), nine studies documented similar severity,
and six had increased severity [57].
A prospective study [63] of 21 patients receiving quadruple
induction CyA-based immunosuppression augmented by MMF2 vol. 56 j 973–983 977
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(n = 12) or by AZA (n = 9) showed that MMF tended to delay
recurrent hepatitis C and to limit initial graft dysfunction, but
there was more severe progression of graft ﬁbrosis with MMF
than with AZA.
In a randomized study [64] of four MMF dose regimens for
8 weeks in 30 patients, no subject became HCV-RNA negative
nor had 1log decrease. In a retrospective matched study of 80
patients with histologically proven HCV recurrence, 40 patients
treated with MMF and CNI tapered for 24 months, and 40 non-
MMF patients [65], the MMF group had reduced ﬁbrosis progres-
sion, graft inﬂammation and ALT levels.
A retrospective evaluation [66] of 3463 HCV transplanted
patients assessed long term outcomes of MMF based on discharge
medication data. Those with MMF, Tac, and steroids compared to
other Tac regimens without MMF had signiﬁcantly increased
four-year survival (79.5% vs. 73.8%; p = 0.002) and graft survival
(74.9% vs. 69.5%; p = 0.024) and less acute rejection (27.3% vs.
32.1%; p = 0.047). However, MMF did not show beneﬁt in terms
of histologically HCV recurrence.
The published data [57] of RCTs and cohort studies showed
that in 2 RCTs comparing MMF to AZA for acute rejection, only
one had less treated rejection with MMF (38.5% vs. 47.7%;
p = 0.025), with no difference in patient and graft survival. No
RCTs have compared MMF and AZA in patients with CNI-
related chronic renal dysfunction. Among two studies evaluat-
ing MMF substituting AZA, one was stopped due to severe
rejection. Recurrent HCV was less severe in 5/9 studies with
AZA compared with only 2/17 using MMF, six of which docu-
mented worse recurrence.
There was no data on HCV recurrence in another large study
based on discharge medications in which patients on MMF at dis-
charge had less progressive renal dysfunction [67]. A retrospec-
tive case-control study [68] in 30 patients evaluated the effect
of MMF monotherapy on recurrent HCV. Fifteen patients were
switched from CNIs to MMF monotherapy, due to renal dysfunc-
tion and metabolic side-effects and were evaluated after
48 weeks; they were matched with 15 patients on CNIs. Patients
on MMF had no worsening in ﬁbrosis vs. an increase in ﬁbrosis in
the CNIs group (p <0.0002).
In conclusion, there is still controversy regarding the best
anti-proliferative agent for HCV recipients. Evidence from well
designed randomized studies is still limited as regards outcomes.
Observational studies suggest that maintenance AZA is associated
with less ﬁbrosis progression compared to MMF.mTOR inhibitors: sirolimus and everolimus
Experimental data and mechanism of action
These inhibit the mammalian target of rapamycin (mTOR) block-
ing interleukin-2 and interleukin-15 induction of proliferation of
T and B cells. Cell growth and angiogenesis are linked with mTOR
activity; mTOR inhibition decreases HCC growth. Sirolimus also
reduces TGFb and procollagen, important factors in the
development of liver ﬁbrosis. Recent data in animal models sug-
gest that sirolimus and everolimus are associated with signiﬁ-
cantly less ﬁbrosis progression and portal hypertension than
treatment with CNIs [69].978 Journal of Hepatology 201Clinical studies
In a non randomized study of 67 HCV transplant patients, 39
received a regimen including sirolimus, and 28 received CNIs
[70]: a signiﬁcant decrease in HCV RNA levels and better survival
was documented in the sirolimus group. However, doses of drugs
were not speciﬁed and protocol biopsies were not performed. In
35 transplant recipients with HCV and HCC, who had developed
renal dysfunction, sirolimus was used: there was less ﬁbrosis
and less likelihood to develop advanced disease and to require
antiviral therapy [71]. However, data on other immunosuppres-
sives was not reported.
There are very few HCV speciﬁc data on everolimus [72] [73].
Only well designed RCT will conﬁrm if mTOR inhibitors are useful
in HCV transplant recipients. The bone marrow suppression may
make it more difﬁcult if antiviral therapy is needed. If the SILVER
study demonstrates beneﬁt in terms of HCC recurrence [74] [75],
then mTOR inhibitors may become standard therapy for HCV
recipients with HCC.Anti-lymphocyte preparations
OKT3, ATG, antiCD25
Anti-lymphocyte preparations are used to treat steroid resistant
acute rejection in some induction regimens [76].
Clinical studies – observational
OKT3 has been associated with ﬁbrosing cholestatic hepatitis
accompanied by very high serum viral loads [8,77–78]. In a group
of 31 HCV transplanted patients, RATG was used initially (n = 16);
thereafter basiliximab or daclizumab (n = 15) [79]. Steroids and
Tac were maintenance therapy. Patient and graft survivals at
6 months were excellent and similar in both groups. HCV recur-
rence was higher with IL-2 receptor inhibitors (80%) compared
to RATG (56%; p = n.s.). In 7 HCV transplanted patients evaluating
ATG for treating acute rejection [80], all patients developed
severe recurrence with signiﬁcant rises in HCV RNA levels, and
one died.
Alemtuzumab use in 38 HCV transplant recipients [81]
resulted in patient and graft survival at one year of 71% and
70%, vs. 65% and 54%, respectively, with conventional treatment,
the latter being quite low. Only 6% pretreated with alemtuzumab
developed rejection during the ﬁrst four months compared to 30%
in the conventionally treated group. HCV replication was worse
with alemtuzumab, but no data for histological recurrence were
provided.
Anti-CD25 use was evaluated retrospectively [82] in 152 HCV
recipients. Together with preemptive antiviral therapy, there was
improved short term mortality of HCV recipients, who were
transplanted with aged organs but no histological data was given.
Clinical studies – randomized trials
Thymoglobulin induction (n = 22) plus Tac was compared to Tac
plus steroids (n = 30) without induction [83]. Patient survival,
rejection rates and HCV recurrence did not differ, but in the thy-
moglobulin group mean time to histological recurrence was
shorter, despite lower baseline HCV RNA loads.2 vol. 56 j 973–983
Table 3. Maintenance corticosteroids for HCV-positive recipients: the case against.
Author, year Immunosuppression No. patients
(total)
Steroids
Filiponi et al.,  
2004 
CyA/AZA/Pred/
Basiliximab   
CyA/AZA/Placebo/
Βasiliximab
74
66
Tapered to 5 mg (3 mo) Similar patient and graft survival at 1 year follow-
up 
Steroid-free group: lower rate of treatment failure
Klintmalm et al.,  
2007 
Tac/Pred
Tac/Pred/MMF
Tac/MMF/Daclizumab
80
79
153
Tapered to 5 mg (3 mo) Steroid-free regimen safe and effective at 
immunosuppression
Llado et al.,  
2008
CyA/Basiliximab/Pred
CyA/Basiliximab
46
43
Withdrawn at 3 mo Steroid-free regimen safe and effective at 2 
year follow-up – ↓ Infectious and metabolic 
Marubashi et al., 
2009
Tac-CyA/MMF/
anti-CD25/Cs 
Tac-CyA/MMF/
anti-CD25  
10
18
Tapered off at 3 mo Living Donor Liver Transplants – HCV recurrence 
less frequent in steroid free (p = 0.009)
Segev et al.,  
2008
Cs-based vs. Cs-free 
immunosuppression
Meta analysis
30 publications – 
19 RCT
Not exclusively liver transplanted – Heterogeneous 
trials – HCV recurrence lower with Cs avoidance 
Sgourakis et al.,  
2009 
Cs-based vs. Cs-free 
immunosuppression
Meta analysis 
21 RCT
Not exclusively HCV transplants: Cs-free 
rejection
HCV population
on HCV recurrence, acute graft hepatitis and 
treatment failure
: Cs-free protocols benefit
protocols advantage on metabolic profile, CMV,
complications – lower severe fibrosis (n.s.)
1 year follow-up – Recurrence not influenced by
Interpretation (fibrosis, survival)
Tac, tacrolimus; Cya, cyclosporine A; AZA, azathioprine; Pred, prednisolone; MMF, mycophenolate mofetil; Cs, corticosteroids; RCT, randomized controlled trials; n.s., not
signiﬁcant.
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Anti-IL-2 receptor antibodies are speciﬁc to the a–chain of the IL-
2 receptor and result in fewer side effects in comparison to ATG.
They are effective at preventing acute rejection in the early post-
transplant period.
Clinical studies – observational
A multicentre, open label exploratory 6-month study had 70
HCV() and 31 HCV(+) patients [84]. Two 20 mg doses of basilix-
imab were given on day 0 and day 4, together with CyA, AZA, and
Cs. Rejection was more frequent in HCV-positive [29%] than HCV-
negative patients [20%], (p = 0.44). More patients in the HCV
group required addition of Tac therapy compared to the HCV-
negative group, although there were no differences in grade of
rejection. The recurrence rate of HCV hepatitis was 48% at
6 months, with no graft loss up to 12 months from HCV
recurrence.
A retrospective comparison of basiliximab induction [85]
(study group 46 patients, HCV n = 10) compared to historical con-
trols (46 patients, HCV n = 13) who received Tac-based immuno-
suppression reported less histological HCV recurrence in the
basiliximab group (24% vs. 71%), but no protocol biopsies were
performed.
Daclizumab was given to 21 HCV+ and 20 HCV, at risk for
neurological or renal complications from CNI [86], together with
MMF and steroids, followed by Tac and steroid taper. Patients
with HCV given daclizumab had an earlier onset of hepatitis,
jaundice, with greater histological activity and more rapid pro-
gression and higher viral loads: 45% developed advanced disease
within 1 year.
Induction therapy was evaluated in the UNOS data base [76].
HCV+ without induction (n = 17,362), HCV+ with induction
(n = 3479), HCV without induction (n = 20,417) and HCV withJournal of Hepatology 201induction (n = 4357). In a multivariate analysis, induction in both
HCV-positive and negative groups was associated with improved
patient (HR 0.91, 95% CI 0.83–0.99) and graft survival (HR 0.88,
95% CI 0.81–0.95). However, the beneﬁt of induction was most
pronounced in those with renal insufﬁciency or with organ perfu-
sion support at transplant, and the differences were quite small
in other patient groups (Table 5).
Clinical studies – randomized trials
A randomized double blind placebo controlled trial reported data
in a subgroup of 133 recipients with HCV (64 basiliximab, 69 pla-
cebo, both groups receiving CyA and Cs) [87]. Clinically suspected
acute rejection episodes were conﬁrmed by liver biopsy. Analysis
of the combined end point of biopsy-conﬁrmed rejection epi-
sodes, HCV recurrence, death or graft loss showed signiﬁcant dif-
ferences in favour of basiliximab for the HCV cohort, at both 6
and 12 months (p = 0.009 and p = 0.035, respectively). However,
the reduced HCV recurrence rate was only 3.3% less with
basiliximab.
In another RCT [49], 140 HCV+ recipients were randomized to
basiliximab + steroids or basiliximab + placebo, both groups
receiving CyA and AZA. Histological recurrence rates of hepatitis
C were similar (41.2% basiliximab and 37.5% non-basiliximab
groups, p = 0.354) but the steroid-free regimen was associated
with signiﬁcantly lower rate of treatment failure (death, graft
loss, withdrawal for adverse events).
A large multicentre RCT [51] randomized 312 HCV recipients
in three arms Tac + Cs (n = 80), Tac + Cs + MMF (n = 79) or dac-
lizumab induction, Tac, MMF (n = 153). At 1 year, patient and
graft survival was not different. Freedom from recurrent HCV
was 61.8 ± 6.2%, 60.1 ± 6.1%, and 67.0 ± 4.3% in arms 1, 2, and 3,
respectively (p = n.s.).
Another RCT [53] randomized HCV transplanted patients to a
steroid-free maintenance regimen using daclizumab induction, or2 vol. 56 j 973–983 979
Table 4. Studies with azathioprine in respect with HCV recurrence.
Author, year No. of patients
(total/HCV)
Outcome Variables Results p value
Hunt et al.,
2001
65/65 HCV recurrence – 
Progression of HCV 
recurrence
Use vs. nonuse of AZA 6/17 vs. 37/48
1/6 vs. 18/37
<0.005
0.014
Berenguer et al., 
2002
522/283 Induction without AZA Associated in univariate analysis -
Berenguer et al., 
2003
554/554 Severe HCV recurrence 
two years)
AZA <12 mo OR 3.24 [95% CI: 1.51-6.96] 0.003
Samonakis et al., 
2005
193/193 Overall survival 
3 mo survival 
AZA at 3 mo
No maintenance AZA
No maintenance AZA
OR 0.3 [95% CI: 0.18-0.64]
OR 0.3 [95% CI: 0.16-0.64]
-
-
-
0.029
Garcia Gonzalez 
et al., 2005
177/85 Acute rejection
Patients and graft survival
Use vs. non-use of AZA Lower acute rejection
Survival: no difference
0.008
n.s.
Eid et al., 
2007
92/92 Use of AZA 
Tac+Cs vs. Tac/AZA/Cs
OR 0.37 [95% CI: 0.14-0.92] 0.033
Manousou et al., 
2009
103/103
Portal hypertension
Use of AZA
Tac vs. Tac/AZA/Cs and portal hypertension
-
Cirrhosis (fibrosis stage 4)
(fibrosis stage ¾ within first
Severe fibrosis
Cirrhosis (fibrosis stage 4)
Stage 4 fibrosis Slower onset of severe fibrosis
AZA, azathioprine; OR, odds ratio; Tac, tacrolimus; Cs, corticosteroids; n.s., not signiﬁcant.
Frontiers in Liver Transplantationsteroid maintenance without induction. Daclizumab had no
impact on hepatic ﬁbrosis progression. Occurrence of acute rejec-
tion was strongly associated with increased hepatic ﬁbrosis at
1 year.
In conclusion, OKT3, ATG, and alemtuzumab for preventing or
treating rejection are associated with severe HCV recurrence.
Data for IL-2 receptor antagonists are contradictory, most studies
showing no harm, but some showing worse recurrence.Key Points
• Corticosteroid pulses and antilymphocyte therapies 
given for acute cellular rejection are associated with 
more severe HCV recurrence; a single course of MP (up
to 3 boluses) for rejection does not appear deleterious
• Tacrolimus and cyclosporine regimens are similar 
in terms of HCV recurrence, but  tacrolimus based 
regimens have better graft and patient survival
• Induction therapy may not have adverse effects on HCV
recurrent disease but further evidence is needed to 
this
• Observational studies show of low dose and
slow tapering of steroids and long term maintenance 
azathioprine
• MMF is as a CNI sparing agent in recipients
with nephrotoxicity, whereas its effect on severity of HCV
recurrence may be harmful compared to azathioprine 
containing regimens, but this requires further evidence
• Rapid changes in immunosuppression or alteration 
in strength of immunosuppression are likely to be 
deleterious for recurrence but the evidence for this is 
scarce
• The development of tolerance and weaning off 
immunosuppression is an appealing prospect for HCV 
recipients, but as yet is not applicable for clinical practice
confirm
benefit
beneficialWeaning off immunosuppression and tolerance
Long-term immunosuppression leads to nephrotoxicity, meta-
bolic disorders, opportunistic infections, and neoplasms. Some
liver transplant recipients can be weaned off all immunosuppres-
sive drugs [88] as they have tolerance to the graft [89] as the liver
seems to have an ‘‘immunological privilege’’ compared to other
transplanted solid organs.
Patients transplanted for HCV cirrhosis represent an ideal
group for weaning strategies. In 34 patients with recurrent HCV
disease [90], complete and permanent immunosuppression with-
drawal was achieved in 24%, but 35% rejected during tapering,
and another 41% developed rejection within eight months.
Weaned patients showed stabilization or improvement of histo-
logical ﬁbrosis, lower necroinﬂammation, and improved liver
function, after a mean follow-up of 45 months. Low blood CyA
trough levels during the ﬁrst post-transplant week and initial ste-
roid-free immunosuppression were independent predictors of
sustained weaning, suggesting this subgroup had less propensity
for rejection.
During follow-up [91] over 6.5 years, seven of the eight orig-
inally tolerant patients, remain alive and in good condition, while
1 died of severe HCV recurrence at 10 years after transplantation
and 6 years after stopping immunosuppression. Four of the 26
patients in whom weaning failed died of HCV recurrence, lung
carcinoma, and acute myocardial infarction, after a mean fol-
low-up of 115 months. The 10-year survival from liver transplan-980 Journal of Hepatology 201tation was comparable (89% vs. 87.5%) to non-weaned patients,
but there was no difference in HCV recurrence histologically.
Unfortunately, induction of tolerance is not a clinical reality,
but in the future, molecular signatures (such as peripheral blood
mononuclear cells’ gene expression proﬁles) might identify
patients in whom immunosuppression can be stopped and this
will be particularly important in HCV recipients [89] .2 vol. 56 j 973–983
Table 5. Induction with anti-lymphocyte preparations.
Author, year HCV patients Outcome Variables Results p value
Nelson et al., 
2001
21 HCV+
20 HCV-
HCV recurrence – 
Histologically progressive 
disease
Daclizumab, MMF,
Cs >Tac/Cs taper No difference in mortality
<0.05
n.s.
Neuhaus et 
al., 2002
133 HCV+ 
64 basiliximab/
69 placebo
Rejection episodes, 
graft loss or death, HCV 
recurrence
Basiliximab or placebo +
CyA/Cs
Analysis favors basiliximab 
[all end points]
0.02
Calmus et al., 
2002
70 HCV-
31 HCV+
Rejection episodes, 
Patient and graft survival 
at 12 mo
Basiliximab, CyA, AZA, Cs Rejection more frequent in HCV+
48% recurrence at 6 mo
0.44
Marcos et al., 
2004
38 HCV out of 76 
adult recipients 
Rejection – Patient and 
graft survival 
anti CD25 (alemtuzumab)
+ standard 
immunosuppression
Worse for HCV, increased 
replication, no data on histological 
recurrence
Filipponi et al., 
2004
140 HCV Histological recurrence, 
treatment failure, acute 
rejection
Basiliximab+Cs or 
Basiliximab+Placebo+ 
CyA/AZA
Treatment failure higher in Bas/
Cs group – Rejection less in Bas/
Cs group 
Recurrence n.s. differences
0.03
0.04
0.354
Kamar et al., 
2005
31 patients Rejection – Patient and 
graft survival at 6 mo
RATG (n = 16)
Basiliximab/Daclizumab 
(n = 15) – Cs/Tac
Similar results in both groups n.s.
Llado et al., 
2006
89 HCV/198 
patients
Rejection – HCV 
recurrence    
Basiliximab+CyA
With Cs/without Cs
Rejection rate similar
HCV recurrence same
Fibrosis, Viremia
0.67
1
n.s.
Klintmalm et 
al., 2007
312 HCV patients Rejection – HCV 
recurrence – Patient and 
graft survival 
Tac+Cs vs. Tac+Cs+MMF 
vs. Daclizumab+Tac+MMF
Excellent patient/graft survival – 
Acute rejection and donor age risk 
factors for HCV recurrence
n.s.
0.001
Kato et al., 
2007
Period 1: 31
Period 2: 39 year protocol biopsy – 
Acute rejection – Steroid 
side effects
Tac+Daclizumab vs. 
Tac+Cs – 
Tac+MMF+Daclizumab 
vs.Tac+MMF+Cs
Cs group more wound infection
and more diabetes
n.s.
0.01
0.003
Urbani et al., 
2008
302 HCV patients Mortality, rejection CyA/AZA/Cs vs.
CyA/Cs vs.
CyA*/Alemtuzumab
Single drug immunosuppressive 
regimen associated with survival 
0.05
Moonka et al., 
2010
17,362 induction-
3479 induction+
Patient and graft 
survival
HCV vs. non HCV, 
Induction ±
Improved 
Patient [HR 0.91] and 
Graft survival [HR 0.88]
0.024
<0.008
Mean fibrosis stage at 1 No benefit in reducing mean
fibrosis at 12 mo
Worse fibrosis with daclizumab –
⁄With extracorporeal photopheresis.
Tac, tacrolimus; Cya, cyclosporine A; MMF, mycophenolate mofetil; Cs, corticosteroids; Bas, basiliximab.
JOURNAL OF HEPATOLOGYConclusions
There are still more questions than answers regarding immuno-
suppression for HCV recipients, despite the advent of new drugs
and a plethora of studies. However, unfortunately most studies
are small and solely observational. Moreover, the few meta-anal-
yses of RCT have signiﬁcant clinical heterogeneity.
Appropriate RCT are still needed, and should evaluate protocol
biopsies at determined intervals, the number of histologically
proven rejection episodes, the interaction of immunosuppressive
agents with HCV replication, donor age, quality, and all factors
should be evaluated in relation to deﬁned clinical outcomes,
e.g. severity of recurrent disease, graft, and patient survival. Cur-
rently, the selection of the appropriate immunosuppression for
the HCV recipient demands a critical approach in examining
and understanding the available literature.
From our review it is clear that the ideal immunosuppression
is not currently known, but less potent maintenance
immunosuppression and avoiding repeated cellular rejection
and its treatment result in slower progression of ﬁbrosis due to
recurrent HCV. Tac is the CNI of ﬁrst choice and low dose steroids
with prolonged tapering may have a modulating effect on liverJournal of Hepatology 201injury. Long term azathioprine may have advantages over myco-
phenolate. There is insufﬁcient data to recommend mTOR inhib-
itors at present.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding of conﬂict of interest with respect to this
manuscript.
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